Description
Mefenamic acid is a fenamate non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, neuroprotective, anticancer, and neuromodulatory activities. Mefenamic acid is a non-selective inhibitor of COX-1 and COX-2 that also potentiates activity at GABA-A receptors. In animal models of cerebral ischemia, mefenamic acid decreases infarct volume, edema, and ischemic brain damage. Additionally, this compound inhibits proliferation in colon cancer cells by altering cell cycle regulators and inhibiting store-operated Ca2+ entry into cells.
References
Khansari PS, Halliwell RF. Evidence for neuroprotection by the fenamate NSAID, mefenamic acid. Neurochem Int. 2009 Dec;55(7):683-8. PMID: 19563851.
Weiss H, Amberger A, Widschwendter M, et al. Inhibition of store-operated calcium entry contributes to the anti-proliferative effect of non-steroidal anti-inflammatory drugs in human colon cancer cells. Int J Cancer. 2001 Jun 15;92(6):877-82. PMID: 11351310.
Halliwell RF, Thomas P, Patten D, et al. Subunit-selective modulation of GABAA receptors by the non-steroidal anti-inflammatory agent, mefenamic acid. Eur J Neurosci. 1999 Aug;11(8):2897-905. PMID: 10457186.
